{
    "nct_id": "NCT06395753",
    "official_title": "A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Locally Advanced/Metastatic Prostate Cancer",
    "inclusion_criteria": "1. Participant with histologically confirmed locally advanced/metastatic prostate cancer\n2. Participant judged by the Study Investigator to be candidate for continuous androgen deprivation therapy (ADT)\n3. Baseline morning serum testosterone levels >150 ng/dL at screening visit\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n5. Life expectancy of at least 6 months\n6. Adequate bone marrow, hepatic, and renal function at the screening visit\n\n[Note: Other protocol and subprotocol-defined criteria apply]\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Previous ADT (neoadjuvant or adjuvant hormonal therapy) for â‰¥6 months duration and <6 months treatment-free interval before start of screening\n2. Indication for androgen deprivation combination therapy\n3. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy\n4. Received chemotherapy or cryotherapy within 8 weeks prior to the start of screening for the treatment of prostate cancer\n5. Abnormal cardiovascular function or diabetes\n6. Use of exogenous testosterone within 6 months before the start of screening\n7. Major surgery within 4 weeks before the start of screening\n8. Cancer disease within the last two years except for prostate cancer and some skin cancers\n\n[Note: Other protocol and subprotocol-defined criteria apply]",
    "miscellaneous_criteria": ""
}